Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART-123 for prevention of oxaliplatin-induced peripheral neuropathy in colon cancer
NCT02792842Phase 2Completed
- Sponsor
- Asahi Kasei Corporation
- Start
- Jul 2016
- Primary completion
- Feb 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of thrombomodulin alfa in chemotherapy-induced peripheral neuropathy (CIPN) (3 arms), sponsored by Asahi Kasei Corporation. Primary endpoints: Cumulative Rates of Participants With NCI-CTCAE Grade 2 or Higher Peripheral Sensory Neuropathy, Least-squares (LS) Means of Functional Assessment of Cancer Therapy/Gynecological Oncology Group-Neurotoxicity-12 (FACT/GOG-Ntx-12) Version 4.0 Score at Cycle 12 and 1 more. Started Jul 2016; status: completed.
02
Drugs
thrombomodulin alfa
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT02792842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02792842.